- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | Reviva Pharmaceuticals: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights | 77 | GlobeNewswire (Europe) | - 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial - - Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative... ► Artikel lesen | |
| 14.11. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 12.11. | Reviva vermeldet Fortschritte bei Studie zur Schizophrenie-Behandlung | 3 | Investing.com Deutsch | ||
| 08.10. | Reviva Pharmaceuticals: Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit | 1 | GlobeNewswire (USA) | ||
| REVIVA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 07.10. | Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst | 31 | Benzinga.com | ||
| 02.10. | Reviva Pharmaceuticals: Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference | 3 | GlobeNewswire (USA) | ||
| 26.09. | Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference | 1 | GlobeNewswire (USA) | ||
| 23.09. | EF Hutton setzt Kaufempfehlung für Reviva Pharmaceuticals-Aktien | - | Investing.com Deutsch | ||
| 23.09. | EF Hutton sets Buy rating on Reviva Pharmaceuticals shares | 1 | Investing.com | ||
| 17.09. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.09. | Reviva Pharmaceuticals: Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia | 250 | GlobeNewswire (Europe) | - Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of schizophrenia - - Additional vocal... ► Artikel lesen | |
| 21.08. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.08. | Reviva Pharmaceuticals stock falls after it prices $5M offering | 1 | Seeking Alpha | ||
| 21.08. | Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules | 2 | GlobeNewswire (USA) | ||
| 15.08. | Reviva Pharmaceuticals GAAP EPS of -$0.26 | 3 | Seeking Alpha | ||
| 14.08. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.08. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 09.07. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.07. | Reviva Pharmaceuticals: Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension | 200 | GlobeNewswire (Europe) | - Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary... ► Artikel lesen | |
| 29.05. | Reviva Pharmaceuticals: Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | 4 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIATRIS | 12,365 | -0,80 % | Viatris Inc. Q3 Profit Decreases, But Beats Estimates | WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS) released a profit for third quarter that decreased from the same period last year but beat the Street estimates.The company's earnings came in at $94.8... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 8,805 | -3,45 % | Grünes Gold!: Gesundheit so wichtig wie nie! Medizinische Revolution durch diese Aktie! | ||
| ASTRIA THERAPEUTICS | 9,050 | -0,55 % | Astria TherapeuticS GAAP EPS of -$0.42 in-line | ||
| NEWRON PHARMACEUTICALS | 7,600 | -0,78 % | Newron SpA Aktie: Stabile Performance trotz Herausforderungen | ||
| CASSAVA SCIENCES | 25,390 | +2,67 % | Cassava Sciences, Inc.: Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer | ||
| ORAMED PHARMACEUTICALS | 2,098 | -2,42 % | Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt | NEW YORK, Oct. 7, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery... ► Artikel lesen | |
| ROCKET LAB USA | 19,020 | -0,63 % | Is Rocket Lab Stock a Millionaire Maker? | ||
| AURINIA PHARMACEUTICALS | 7,558 | -3,40 % | Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development | ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter and nine months... ► Artikel lesen | |
| LIPOCINE | 4,730 | 0,00 % | Lipocine Inc. - 8-K, Current Report | ||
| BOIRON | 29,700 | +1,37 % | BOIRON: EVOLUTION OF GOVERNANCE | July 3rd, 2024
The Board of Directors of Laboratoires BOIRON, meeting today under the chairmanship of Thierry BOIRON, has enacted an evolution of the Group's governance.
In this context, Thierry... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 5,640 | 0,00 % | Kazia Therapeutics Limited: Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring ... | Treatment with 45mg paxalisib and radiotherapy demonstrated 67% partial response (PR)
Over two-thirds of the patients at maximum tolerated dose (MTD) achieved intracranial response which compares favorably... ► Artikel lesen | |
| ALLERGY THERAPEUTICS | 0,060 | 0,00 % | Allergy Therapeutics - Notice of 2024 Annual General Meeting | ||
| HARROW | 42,440 | 0,00 % | Pre-market Movers: California BanCorp, Harrow, Inc., Quantum Computing, BTC Digital, Calidi Biotherapeutics | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.15 A.M. ET).In the Green California BanCorp. (BCAL) is up over 33% at $23.01.
Quantum... ► Artikel lesen | |
| MEDICINOVA | 1,700 | 0,00 % | MediciNova, Inc.: MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders | LA JOLLA, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| ESSA PHARMA | 1,745 | 0,00 % | ESSA Pharma: NBC-Anlegerclub feiert schnelle +23% Rendite! | Der No Brainer Club (NBC) hat erneut sein Gespür für unterbewertete Biotech-Perlen unter Beweis gestellt. Mit ESSA Pharma konnten Mitglieder in diesem fulminanten Biotech-Herbst innerhalb weniger Tage... ► Artikel lesen |
REVIVA PHARMACEUTICALS HOLDINGS INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,220 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVIVA PHARMACEUTICALS HOLDINGS INC finden Sie auf Wallstreet Online.
